Analysis of the interferon gamma (rs2430561, +874T/A) functional gene variant in relation to the presence of cardiovascular events in rheumatoid arthritis by García-Bermúdez, Mercedes et al.
Analysis of the Interferon Gamma (rs2430561, +874T/A)
Functional Gene Variant in Relation to the Presence of
Cardiovascular Events in Rheumatoid Arthritis
Mercedes Garcı´a-Bermu´dez1., Raquel Lo´pez-Mejı´as2., Carlos Gonza´lez-Juanatey3, Alfonso Corrales2,
Gema Robledo1, Santos Castan˜eda4, Jose´ A. Miranda-Filloy5, Ricardo Blanco2, Benjamı´n Ferna´ndez-
Gutie´rrez6, Alejandro Balsa7, Isidoro Gonza´lez-Alvaro4, Carmen Go´mez-Vaquero8, Javier Llorca9,
Javier Martı´n1", Miguel A. Gonza´lez-Gay2*"
1 Instituto de Parasitologı´a y Biomedicina Lo´pez-Neyra, Consejo Superior de Investigaciones Cientı´ficas, IPBLN-C.S.I.C., Granada, Spain, 2Department of Rheumatology,
Hospital Universitario Marque´s de Valdecilla, IFIMAV, Santander, Spain, 3Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, 4Department of Rheumatology, Hospital
Universitario La Princesa, IIS-Princesa, Madrid, Spain, 5Department of Rheumatology, Hospital Xeral-Calde, Lugo, Spain, 6Department of Rheumatology, Hospital Clı´nico
San Carlos, Madrid, Spain, 7Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 8Department of Rheumatology, Hospital Universitario de
Bellvitge, IDIBELL, LHospitalet del Llobregat, Barcelona, Spain, 9Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and
CIBER Epidemiologı´a y Salud Pu´blica (CIBERESP), IFIMAV, Santander, Spain
Abstract
Objective: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV)
morbidity and mortality. Since interferon-gamma (IFN-c) has a direct effect on inflammation, in this study we assessed the
potential association of the IFNG functional gene variant rs2430561 with CV disease in patients with RA.
Methods: One thousand six hundred and thirty-five patients fulfilling the 1987 American College of Rheumatology
classification criteria for RA were genotyped for the IFNG (rs2430561, +874T/A) gene polymorphism using TaqMan
genotyping assay. Patients were stratified according to the presence of CV events or not. Logistic regression models to
explain the presence of CV disease according to the IFNG rs2430561 allele distribution were performed. The potential
influence of this variant in the development of subclinical atherosclerosis was also analyzed in a subgroup of patients with
no history of CV events to determine carotid artery intima-media thickness (IMT) (n = 286) and presence of carotid plaques.
Levels of the cytokine were determined in a subgroup of patients by ELISA.
Results: Adjusted logistic regression model disclosed that presence of the minor allele A was not associated with increased
risk of suffering CV events in RA patients. Besides, differences did not achieve statistical significance regarding carotid IMT
and presence of carotid plaques in RA patients carrying IFNG rs2430561 variant allele. Levels of IFN-c were higher in patients
who had suffered CV events compared to patients who did not.
Conclusion: Our results do not support a role of IFNG rs2430561 (+874T/A) functional gene variant in the development of
CV disease in RA patients.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
associated with high risk of cardiovascular (CV) disease. Athero-
sclerosis is the leading cause of increased CV morbidity and
mortality in RA patients [1]. Besides classic CV risk factors, ‘‘high-
grade’’ systemic inflammation and immune dysregulation play a
crucial role in the development of the accelerated atherosclerosis
observed in RA [1,2,3]. With respect to this, atherosclerosis and
RA share inflammatory mechanisms that may explain the
augmented incidence of CV events observed in patients with RA
[3,4]. Moreover, recent studies have disclosed the importance of
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genetic factors in the development of CV disease in patients with
RA [5,6,7,8,9,10].
Two T cell-derived cytokines of potential importance in RA are
interferon gamma (IFN-c) and interleukin (IL)-17. Although only
small amounts of IFN-c are produced by synovial T cells, this
cytokine serves as a marker for the subset of activated T cells
known as Th1 helper cells. These cells promote and amplify
autoimmune diseases. IFN-c also has a direct effect on inflamma-
tion by increasing major histocompatibility complex (MHC) class
II expression as well as priming macrophages to produce
inflammatory and tissue-damaging mediators such as TNF-a,
proteases, reactive oxygen species, and nitric oxide [11].
IFN-c is a pleiotropic soluble cytokine with antiviral and anti-
tumor properties. This cytokine is found in RA patients synovium
and synovial fluid [12], and polymorphisms within its gene
sequence may be biologically plausible candidates for influencing
the incidence and severity of RA [13]. With respect to this, the
functional Single Nucleotide Polymorphism (SNP) at position
+874 of the IFNG gene (rs2430561) [NCBI Reference Sequence:
NT_029419.12] maps to a putative nuclear factor-kB (NF-kB)
binding site. The presence of T allele in this functional variant
improves the NF-kB binding efficiency leading to increased IFN-c
expression in vitro [14].
Association of a polymorphic microsatellite located in the first
intron of the IFNG gene with susceptibility to RA was reported
[15], although other studies failed to confirm the association
between the IFNG gene polymorphism and RA susceptibility or
severity [13,16]. IFNG repeat polymorphism is in complete linkage
disequilibrium with the rs2430561 functional variant [14].
Association of IFNG gene polymorphism with systemic lupus
erythematosus has also been described in Korean population [17]
and polymorphisms in the IFNG/IL-6 gene region may contribute
to sex bias in susceptibility to RA [18]. No association was
reported at Genome-wide association analysis level for IFNG and
RA, although a significant association was reported for a variant
located near IFNG gene and ulcerative colitis [19].
Atherosclerosis is a chronic inflammatory disease. In the general
population, in individuals not affected by RA, IFN-c is highly
expressed in atherosclerotic lesions and has emerged as a
significant factor in the development and progression of CV
disease. IFN-c is of main importance in the development of
oxidative stress for antimicrobial and anti-tumoral defense within
the cell-mediated immune response. In CV disease, biochemical
reactions induced by interferon-gamma may have detrimental
consequences for host cells. IFN-c is the most important trigger for
the formation and release of reactive oxygen species. Chronic
reactive oxygen species -production leads to the depletion of
antioxidants like vitamin C and E and glutathione, with a
consequence that oxidative stress develops. Oxidative stress plays a
major role in the atherogenesis and progression of CV disease, and
it may also account for the irreversible oxidation of other
oxidation-sensitive substances like B-vitamins [20]. Previous
studies have also shown that IFN-c is the main trigger for
production and release of reactive oxygen species in endothelium,
and a subtype of T cells involved in rheumatoid synovitis and
atherosclerosis produce large amounts of IFN-c [20]. Further-
more, IFN-c has an important role in atherosclerosis and plaque
Table 1. Demographic characteristics of the RA patients included in the study.
Variables N=1635
Females 1215 (74.31)
Age of patients at the time of disease diagnosis, years, median (IQR) 54 (43–64)
Time follow up, years, median (IQR) 10.2 (5–17)
Anti-CCP positive (n = 1330) 766 (57.59)
Rheumatoid Factor positive (n = 1604) 1106 (68.95)
Cardiovascular events 332 (20.31)
Ischemic heart disease 157 (9.63)
Cerebrovascular accidents 78 (4.78)
Heart failure 91 (5.76)
Peripheral arteriopathy 39 (2.46)
Hypertension (n = 1621) 666 (41.09)
Diabetes mellitus (n = 1616) 216 (13.37)
Dyslipidemia (n = 1619) 643 (39.72)
Obesity (n = 1534) 359 (23.40)
Smoking habit (n = 1552) 447 (28.80)
Except where indicated otherwise, values are n (%). IQR: Interquartile Range. Anti-CCP: Anti-Cyclic Citrullinated Peptide antibodies.
doi:10.1371/journal.pone.0047166.t001
Table 2. Differences in genotype and allele frequencies of
IFNG rs2430561 functional gene variant between RA patients
with CV events versus patients without CV events.
IFNG +874T/A
With CV
events
Without CV
events p OR [95% CI]
TT 75 (23.08) 307 (24.07) Ref.
TA 179 (55.08) 653 (52.53) 0.45 1.12 [0.82–1.53]
AA 71 (21.85) 283 (22.77) 0.89 1.03 [0.70–1.50]
TA+AA 250 (76.93) 936 (75.30) 0.54 1.09 [0.81–1.47]
T 329 (50.62) 1267 (50.97)
A 321 (49.38) 1219 (49.03) 0.87 1.01 [0.85–1.21]
CV: Cardiovascular. Except for OR, values are number (%). OR [95% CI]: Odds
Ratio with 95% Confidence Interval.
doi:10.1371/journal.pone.0047166.t002
IFN-gamma and Cardiovascular Disease in RA
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disruption enhancing expression of adhesion molecules on
endothelial cells [21]. IFN-c can also recruit macrophages and
T cells into plaque, contributing to production of reactive oxygen
species, inhibiting collagen production, stimulating matrix metal-
loproteinases, and inducing tissue factor expression [1,22,23].
Taking account all of these evidences, the main goal of this
study was to assess for first time the potential implication of IFNG
functional gene variant rs2430561 (+874T/A) in the risk of CV
disease of patients with RA.
Patients and Methods
Patients and Study Protocol
Between March 1996 and September 2008, 1635 consecutive
patients that fulfilled the 1987 American College of Rheumatology
classification criteria for RA [24] were recruited from the
Rheumatology Outpatient Clinics of Hospital Xeral-Calde (Lugo),
Hospital Clı´nico San Carlos (Madrid), Hospital Universitario La
Paz (Madrid), Hospital Universitario de La Princesa (Madrid),
Hospital Universitario Bellvitge (Barcelona), and Hospital Uni-
versitario Marque´s de Valdecilla (Santander), Spain. Patients were
assessed for differences in the IFNG rs2430561 functional gene
polymorphism.
Ethics statement. A subject’s written consent was obtained
according to the declaration of Helsinki, and the design of the
work was approved by the Ethics Committee of the different
centers that collaborated in the study.
Between December 2009 and January 2010 patient’s clinical
records were examined until patient’s death, loss of follow-up or
December 1st, 2009. Information on the main demographic and
clinical data regarding clinical characteristics of the patients
enrolled in the study, classic CV risk factors and CV events of
patients for whom clinical information was available at the time of
the study (n = 1635) were registered and are shown in Table 1.
Clinical definitions for classic CV risk factors and CV events
(ischemic heart disease, heart failure, cerebrovascular accident or
peripheral arteriopathy) were established as previously described
[5,25]. A CV event was considered to be present if the patient had
ischemic heart disease, heart failure, cerebrovascular accident or
peripheral arteriopathy. The definition of ischemic heart disease
included acute coronary syndromes with or without persistent ST-
segment elevation and chronic coronary heart disease. Ischemic
heart disease was diagnosed if any of the following criteria were
satisfied: a recorded diagnosis of ischemic cardiopathy, on account
of some acute coronary syndrome (acute myocardial infarction or
unstable angina), the presence of pathological Q waves in the
electrocardiogram, and coronary images showing .50% stenosis
of at least one coronary vessel. Data regarding the clinical
presentation of heart failure were also collected from all patients. A
patient was considered to have a cerebrovascular accident when
he/she had a stroke and/or transient ischemic attacks. Strokes
were classified according to their clinical features and they were
confirmed by computed tomography and/or magnetic resonance
imaging. Transient ischemic attacks were diagnosed if the
symptoms were self-limited in less than 24 hours, without residual
neurological damage. Peripheral arterial disease was considered to
be present if it was confirmed by Doppler and arteriography
[5,25].
To determine the potential association between the IFNG
rs2430561 gene variant and the presence of subclinical atheroscle-
rosis, between March 2007 and December 2010 a random subgroup
of patients from the Lugo and Santander hospitals with no previous
history of CV events was selected. In this regard, as previously
reported, we assessed carotid ultrasonography studies in the
common carotid artery to determine the carotid artery intima-
media wall thickness (IMT) and presence of carotid plaques [26] in
286 patients. Also, an evaluation of endothelial function was assessed
by a brachial artery reactivity study in 148 patients. Flow-mediated
endothelium-dependent vasodilatation-FMD (post-ischemia) and
endothelium-independent-NTG (post-nitroglycerin) vasodilatation
were measured by brachial ultrasonography as previously described
[26,27].
IFNG Genotyping
Genomic DNA was isolated from whole blood using the
QIAamp Blood DNA mini kit according to the manufacturer’s
instructions (Qiagen lnc, Hilden, Germany). Allelic discrimination
with TaqMan real-time PCR was used to genotype for polymor-
phism in the IFNG +874T/A gene with the following primers:
forward 59-TGCGAGTGTGTGTGTGTGT-39 and reverse 59-
CAGACATTCACAATTGATTTTATTTTACAACACAAA-39.
Probe 1: 59MGB- TGTGTGTGTGATTTGA 39 –FAM and
probe 2: 59MGB- TGTGTGTGAGATTTGA 39 -VIC
(rs2430561). The PCR and end point analysis was performed in
a volume of 4 ml containing 15 ng genomic DNA. The PCR was
Table 3. Logistic regression model to explain the presence of
CV disease in patients with RA according to IFNG rs2430561
allele distribution.
IFNG +874T/A p OR [95% CI] p* OR [95% CI]*
A vs. T 0.87 1.01 [0.85–1.21] 0.56 1.08 [0.84–1.39]
*Analyses adjusted for gender, age at rheumatoid arthritis diagnosis, follow-up
time from the disease diagnosis, anti-CCP status, and long-standing CV risk
factors: hypertension, diabetes mellitus, dyslipidemia, obesity and smoking
habit. OR [95% CI]: Odds Ratio with 95% Confidence Interval.
doi:10.1371/journal.pone.0047166.t003
Table 4. Comparison of carotid artery intima media thickness
(IMT) according to IFNG rs2430561 variant.
rs2430561 IMT mm, mean (SD) p
TT (n = 73) 0.74 (0.16)
TA (n = 153) 0.75 (0.17)
AA (n = 60) 0.71 (0.17)
Model 0.33
T (n = 299) 0.74 (0.17)
A (n = 273) 0.73 (0.17) 0.45
doi:10.1371/journal.pone.0047166.t004
Table 5. Logistic regression model to explain the presence of
carotid plaques in patients with RA according to IFNG
rs2430561 allele distribution.
p OR [95% CI] p* OR [95% CI]*
rs2430561 A vs. T 0.60 1.09 (0.78–1.53) 0.25 1.31 (0.83–2.07)
*Analyses adjusted for gender, age at rheumatoid arthritis diagnosis, follow-up
time from the disease diagnosis, anti-CCP status and classic cardiovascular risk
factors: hypertension, diabetes mellitus, dyslipidemia, obesity and smoking
habit. OR [95% CI]: Odds Ratio with 95% Confidence Interval.
doi:10.1371/journal.pone.0047166.t005
IFN-gamma and Cardiovascular Disease in RA
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accomplished with the following amplification protocol: denatur-
ation at 95uC for 10 minutes, followed by 45 cycles of denaturation
at 95u for 15 seconds, and then annealing and extension at 60uC
for 1 minute, in a 7900 HT Real-Time polymerase chain reaction
(PCR) system, according to the conditions recommended by the
manufacturer (Applied Biosystems, Foster City, CA, USA).
Negative controls and duplicate samples were included to check
the accuracy of genotyping.
Serum IFN-c Levels Determination
Cytokine serum level was determined by Human IFN-c
Quantikine ELISA Kit (R & D Systems Europe, Ltd. Abingdon,
UK) in 153 patients from Hospital Universitario Marque´s de
Valdecilla (Santander), following manufacturer instructions.
Statistical Analysis
All genotype data were checked for deviation from Hardy-
Weinberg equilibrium (HWE) using http://ihg.gsf.de/cgi-bin/
hw/hwa1.pl. Comparison of proportions was carried out using x2
test or Fisher test, when required. Strength of associations between
CV events and genotypes or alleles of IFNG +874T/A gene
polymorphism were estimated using odds ratios (OR) and 95%
confidence intervals (CI), via logistic regression; estimates were
further adjusted for sex, age at RA diagnosis, follow-up time,
presence of anti-Cyclic Citrullinated peptide (anti-CCP) antibod-
ies, and traditional CV risk factors (hypertension, diabetes mellitus,
dyslipidemia, obesity and smoking habit) as potential confounders.
The association between genotypes of the IFNG functional
variant and subclinical atherosclerosis markers or IFN-c serum
levels were tested using unpaired t test to compare between 2
groups, and one-way analysis of variance (ANOVA) to compare
among more than two groups. Moreover, we also tested the
association between these parameters and alleles using analysis of
covariance (ANCOVA) adjusting for sex, age and duration of the
disease at the time of the ultrasonographic study and traditional
CV risk factors.
Statistical significance was defined as p#0.05. All analyses were
performed with STATA statistical software 9.1 (Stata Corp.,
College Station, TX, USA). Statistical power for the study was
calculated using ‘‘CaTS - Power Calculator for Two Stage
Association Studies’’ (http://www.sph.umich.edu/csg/abecasis/
CaTS/) [28].
Results
This multicentric study included 1635 RA patients. Information
on the main demographical data, clinical characteristics of the RA
patients enrolled in the current study, CV risk factors and CV
events of patients is shown in Table 1. Among them, 332
(20.31%) experienced CV events: ischemic heart disease, heart
failure, cerebrovascular accident or peripheral arteriopathy. With
this sample size, the study had 73% statistical power to detect an
OR equal to or higher than 1.25 in alleles present in 49% of the
patients at the stated significance level (a= 0.05), type II error rate
of 0.20 and a prevalence of the disease in Spanish population
0.005 [29]. The study reached a genotyping success .95.9%.
Influence of the IFNG rs2430561 Functional
Polymorphism in the Risk of CV Disease in RA Patients
Initially, we analyzed the genotype and allele distribution of the
IFNG rs2430561 (+874T/A) polymorphism regarding the presence
or absence of CV disease in RA patients (Table 2). Genotype
frequencies were conformed to Hardy-Weinberg equilibrium
(p.0.01). No differences in the frequency of A allele was found
in patients who suffered or did not CV events (49.38% vs. 49.03%);
neither statistically significant differences in the genotype and
allele frequencies were found (p = 0.89, p = 0.87, respectively) when
patients who had experienced CV disease were compared with
those who had not suffered any kind of CV events.
Logistic Regression Model to Explain the Presence of CV
Disease in RA Patients According to IFNG rs2430561
Allele Distribution
In a further step, we constructed a logistic regression model
analysis to explain the presence of CV disease according to the
IFNG rs2430561 allele distribution, which was adjusted for classic
CV risk factors, sex, age at the time of RA diagnosis, follow-up
time from the disease diagnosis and anti-CCP status. No
statistically significant differences on the risk of suffering CV
events in this series of patients with RA were detected (p = 0.56,
Table 6. IFN-c serum levels (pg/ml) in a subsample of
patients (n = 153) with RA stratified according to the presence
or absence of CV events.
Serum IFN-c levels,
mean (SD) p p*
Patients without CV events
(n = 81)
32.86 (81.93)
Patients with CV events (n = 72) 57.54 (97.18) 0.09 0.04
*Analyses adjusted for gender, age at RA diagnosis, follow-up time from the
disease diagnosis, presence or absence of shared epitope, and classic
cardiovascular risk factors.
doi:10.1371/journal.pone.0047166.t006
Table 7. IFN-c levels (pg/ml) in patients without CV events (left) or with CV events (right) according to genotypes and allele
distribution of rs3430561 polymorphism.
IFNG +874T/A without CV events, mean (SD) p IFNG +874T/A With CV events, mean (SD) p
TT (17) 11.47 (19.84) TT (18) 99.90 (133.79)
TA (42) 42.17 (103.65) TA (36) 38.39 (79.17)
AA (21) 33.13 (62.35) 0.44 AA (18) 53.49 (77.07) 0.09
TA+AA (63) 39.16 (91.53) 0.22 TA+AA (54) 43.42 (78.08) 0.03
T (76) 28.44 (79.23) T (72) 69.15 (112.35)
A (84) 37.65 (84.86) 0.48 A (72) 45.94 (77.41) 0.15
doi:10.1371/journal.pone.0047166.t007
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OR 1.08 [95% CI 0.84–1.39]) (Table 3). In addition, we assessed
the influence of the variants in the occurrence of cardiac ischemic
events, heart failure or cerebrovascular accidents. Still, no
significant association was found (adjusted p = 0.74, OR 1.06
[95% CI 0.74–1.53]; p = 0.55, OR 0.88 [95% CI 0.59–1.32];
p = 0.56, OR 1.14 [95% CI 0.73–1.80], respectively). Besides, no
significant associations were detected when we analyzed our
cohort of patients divided by sex, anti-CCP status, or presence of
hypertension, diabetes mellitus or dyslipidemia (data not shown).
IFNG rs2430561 Functional Gene Polymorphism and
Subclinical Atherosclerosis
Since the development and progression of atherosclerosis can be
monitored using non invasive surrogate markers such as increased
carotid artery intima-media thickness and presence of carotid
plaques, we performed carotid ultrasonography to determine these
parameters.
No statistically significant differences were observed among
patients carrying the different genotypes or alleles of the IFNG
rs2430561 (Table 4).
This study had .99% statistical power to detect a difference in
carotid IMT of 0.1 mm or higher between T and A, or between
TT and TA. Statistical power was .93% to detect a variation of
0.1 or higher in carotid IMT between TT and AA.
In the ANCOVA model adjusted for sex, age at the time of the
ultrasonographic assessment, follow-up time, absence or presence
of shared epitope and classic CV risk factors, no significant
differences were found according to IFNG rs2430561 functional
gene SNP (p = 0.63).
In keeping with results from carotid ultrasonography, no
statistically significant differences were found in genotypes or alleles
of patients who have carotid plaques vs. who did not have them in
logistic regression model crude or adjusted by sex, age at rheumatoid
arthritis diagnosis, follow-up time from the disease diagnosis, anti-
CCP status and traditional CV risk factors (Table 5).
In our study, decreased FMD% were observed in RA patients
carrying IFNG rs2430561 variant allele A (4.80 vs. 5.89), although
the difference did not achieve statistical significance (p = 0.20),
neither in the adjusted ANCOVA model (p = 0.11).
IFNG rs2430561 Functional Variant and IFN-c Serum
Levels in RA Patients
The potential association between IFN-c serum levels and CV
events was assessed in 153 patients stratified according to the
presence of CV events or not. As shown in Table 6, RA patients
with CV events had higher levels of IFN-c serum levels than those
who did not experience CV events (adjusted p value = 0.039).
However, no statistically differences were observed when patients
without or with CV events were stratified according to IFNG
rs2430561 genotypes (Table 7). Nevertheless, an ANCOVA
model adjusted for sex, age at RA diagnosis, follow-up time from
disease diagnosis, and classic CV risk factors, disclosed a
marginally significant p value (0.052) when we compared the
IFN-c levels of patients carrying A allele with CV disease against
patients who did not develop CV disease at the time of the study
(Table 8).
Discussion
To the best of our knowledge, this is the first study aimed to
investigate the role of IFNG gene in the development of CV events
in a population of RA patients. Our results do not support role of
the IFNG rs2430561 (+874T/A) functional gene polymorphism in
the increased risk of CV events in patients with RA.
The atherosclerotic lesion contains cytokines that promote a
Th1 response (rather than a Th2 response). Activated T cells
therefore differentiate into Th1 effector cells and begin producing
the macrophage-activating cytokine IFN-c. This cytokine im-
proves the efficiency of antigen presentation and augments
synthesis of the proinflammatory cytokines TNF-a and IL-1.
Acting synergistically, these cytokines promote the production of
many inflammatory and cytotoxic molecules in macrophages and
vascular cells. All these actions tend to promote atherosclerosis
[21]. With respect to this, it is known that patients with RA often
have a ‘‘silent’’ history of coronary artery disease, with augmented
frequency of myocardial infarction and sudden death [30].
Previous studies have described expression of IFN-c by
macrophages and endothelial cells within human atherosclerotic
lesions [20]. Endothelial dysfunction in RA patients may persist in
some patients with RA even when successful response to therapy is
achieved [31]. In accordance with that, Kerekes et al. reported that
serum levels of IFN-c were significantly higher in patients with RA
and low FMD values than in those with high FMD% values [32].
In our study decreased FMD were observed in RA patients
carrying IFNG rs2430561 variant allele A, although the difference
did not achieve statistical significance.
On the other hand, anti-TNF therapy is able to decrease the
proportion of peripheral Th1, Th17 and IFN-c-producing CD8+ T
cells in RA patients [33], with simultaneous increase in the
percentages of Tregs and, remarkably, in IFN-c-producing NK cells.
Amezcu´a-Guerra et al. described a subgroup of patients with
aggressive RA that had high serum concentrations of IFN-c and
persistent endothelial dysfunction despite successful anti-arthritic
therapy [31]. We also observed increased IFN-c levels in patients
with CV events in our study. However, no statistically significant
association between serum levels of IFN-c and IFNG rs2430561
genotypes was found in our series, although the adjusted
ANCOVA model disclosed a marginally significant p value when
we compared de IFN-c levels of patients carrying A allele with CV
disease against patients who did not develop CV disease at the
time of the study. The AA homozygote for IFNG +874T/A
polymorphism was associated with adverse outcome, worse
prognosis as well as with measures of disease severity in idiopathic
dilated cardiomyopathy in a recent study [34].
Intriguingly, patients with RA exhibit expansion of the Th1-
CD4+CD28null cell population in the peripheral blood, which
correlates with higher frequency of extraarticular manifestations,
increased carotid IMT, and decreased FMD% values, supporting
the concept that CD4+CD28null cells may sustain synovial
inflammation and promote atherosclerosis in these patients [35],
as they have been implicated in atherosclerotic plaque disruption
[36] and in all phases of atherosclerotic process [37]. Our results of
endothelial dysfunction although not reaching statistical signifi-
cance, are in agreement with those studies and observations.
Table 8. Comparison of IFN-c levels in patients with or
without CV events according to IFNG rs2430561 alleles in an
adjusted ANCOVA model.
With CV events without CV events
rs2430561, p A vs. T* 0.052 0.58
*Analyses adjusted for gender, age at rheumatoid arthritis diagnosis, follow-up
time from disease diagnosis, and classic cardiovascular risk factors:
hypertension, diabetes mellitus, dyslipidemia, obesity and smoking habit.
doi:10.1371/journal.pone.0047166.t008
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However, we have not been able to demonstrate association
between IFNG +874T/A functional polymorphism and the risk of
suffering CV events in Spanish RA patients.
Nevertheless, it is possible that besides genetic influence,
additional factors may influence IFN-c levels, as immune response
in RA may be the result of a complex network of pro- and anti-
inflammatory mediators. Taken together all these observations, it
is possible that IFNG along with other genes implicated in the
inflammatory response may contribute to the development of the
high-grade systemic inflammation status seen in RA patients that
could explain the increased CV morbidity and mortality reported
in these patients. In addition, it is likely that the relatively low
statistical power of the study to detect small effects may explain, at
least in part, our negative results.
In summary, our results do not show a direct influence of the
IFNG rs2430561 (+874T/A) functional gene polymorphism in the
increased risk of CV events observed in patients with RA. Further
studies need to be carried out to enlighten the role of this gene in
the predisposition to CV disease in RA patients.
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